Delving into the Latest Updates on Henan University with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Infectious Diseases

Small molecule drug

Fusion protein

Recombinant polypeptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Infectious Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	6
Monoclonal antibody	1
Fusion protein	1
Recombinant polypeptide	1

Top 5 Target	Count

CGL(cystathionine gamma-lyase)	2
PDL1(Programmed death-ligand 1)	1
DR5(Tumor necrosis factor receptor superfamily member 10B)	1
p53(Tumor protein p53)	1
ACE2(Angiotensin-converting enzyme 2)	1

Targeted therapies have revolutionized traditional cancer treatments by precisely targeting tumor cells, enhancing efficacy and safety. Despite this advancement, the proportion of cancer patients eligible for such therapies remains low due to the absence of suitable targets. Here, we investigate whether the translocation of the immunogenic cell death (ICD) marker calreticulin (CALR) from the endoplasmic reticulum (ER) to the cell surface following ICD induction can serve as a target for targeted therapies. To target CALR, a nanobody Nb215 identified from a naïve VHH phage library with high binding affinity to both human and mouse CALR was employed to engineer probiotic EcN 1917. Our results demonstrated that CALR nanobody-modified EcN-215 coupled with the photothermal dye indocyanine green (ICG) was able to exert NIR-II imaging-guide photothermal therapy (PTT). Moreover, PTT with EcN-215/ICG can reshape the tumor microenvironment by enhancing the infiltration of CD45⁺CD3⁺ T cells and CD11b⁺F4/80⁺ macrophages. Furthermore, the antitumor activity of CALR-targeted EcN-215/ICG is synergistically enhanced by blocking CD47-SIRPα axis. Collectively, our study provides a proof of concept for CALR-targeted therapy. Given that CALR translocation can be induced by various anticancer therapies across numerous tumor cell lines, CALR-targeted therapies hold promise as a novel approach for treating multiple types of cancers.

01 Feb 2025·Bioelectrochemistry

Electrochemical biosensor based on functional nanomaterials and horseradish peroxidase for the determination of luteolin in peanut shell, honeysuckle and perilla

Article

Author: Yousefi, Reza ; Ma, Lin-Lin ; Ning, Yan-Na ; Abdalbage Mohammed Abdalsadeg, Sanad ; Akbar Moosavi-Movahedi, Ali ; Hong, Tao ; Hong, Jun ; Xu, Ke-Xin ; Chen, Yu-Jie ; Xiao, Bao-Lin ; Li, Yu-Ying

Constructing a biosensor to detect luteolin content accurately is essential, especially considering its specific health benefits at certain concentrations. In this work, the reaction of HRP catalyzed luteolin could be successfully applied in electrocatalytic processes, the oxidation process of electron loss and dehydrogenation occurring on the electrode replaced the hydrogen receptor role of H₂O₂ in the HRP biocatalytic process. This oxidation reaction had an apparent current response, thus achieving accurate measurement of luteolin. On this biosensor, CTAB was used to disperse MWCNTs, and BSA was used to improve the hydrophobicity of MWCNTs, which was conducive to the subsequent AuNPs fixation of HRP. Three detection methods (LSV, DPV and SWV) for the detection of luteolin were compared and showed that SWV method had a wider linear range (1 × 10^-8-2 × 10^-5 M) and lower detection limit (8 × 10^-10 M). The determination of luteolin in Traditional Chinese Medicine (TCM) by high performance liquid chromatography (HPLC) and biosensor was almost identical. Therefore, this biosensor could successfully replace HPLC in detecting luteolin in TCM.

01 Feb 2025·Biomaterials

A dendritic cell-recruiting, antimicrobial blood clot hydrogel for melanoma recurrence prevention and infected wound management

Article

Author: Yuan, Jing ; Li, Xin-Ying ; Zhou, Jing-Sheng ; Gao, Jie ; Zhou, Xuan ; Zhang, Hui-Qi ; Xin, Zhong-Yuan ; Zhang, Xin-Yi ; Chen, Cui-Min ; Zhang, Xiao-Wei ; Pu, Xiao-Hui ; Zhang, Zhuan-Zhuan ; Lu, Zheng-Mao ; Jiang, Xiang-He ; Shi, Te ; Liu, Wen-Shang ; Li, Mei-Gui ; Li, Meng

Surgical resection, the mainstay for melanoma treatment, faces challenges due to high tumor recurrence rates and complex postoperative wound healing. Chronic inflammation from residual disease and the risk of secondary infections impede healing. We introduce an innovative, injectable hydrogel system that integrates a multifaceted therapeutic approach. The hydrogel, crosslinked by calcium ions with sodium alginate, encapsulates a blood clot rich in dendritic cells (DCs) chemoattractants and melanoma cell-derived nanovesicles (NVs), functioning as a potent immunostimulant. This in situ recruitment strategy overcomes the limitations of subcutaneous tumor vaccine injections and more effectively achieves antitumor immunity. Additionally, the hydrogel incorporates Chlorella extracts, enhancing its antimicrobial properties to prevent wound infections and promote healing. One of the key findings of our research is the dual functionality of Chlorella extracts; they not only expedite the healing process of infected wounds but also increase the hydrogel's ability to stimulate an antitumor immune response. Given the patient-specific nature of the blood clot and NVs, our hydrogel system offers customizable solutions for individual postoperative requirements. This personalized approach is highlighted by our study, which demonstrates the synergistic impact of the composite hydrogel on preventing melanoma recurrence and hastening wound healing, potentially transforming postsurgical melanoma management.

100 Deals associated with Henan University

Login to view more data

100 Translational Medicine associated with Henan University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

6

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

I157172 ( CGL )	Breast Cancer More	Preclinical
Homospermidineplatin ( p53 )	Neoplasms More	Preclinical
I194496 ( CGL )	Triple Negative Breast Cancer More	Preclinical
YLZ-F5 ( PLK4 )	Ovarian Cancer More	Preclinical
4-t(Henan University)	Staphylococcus Aureus Infections More	Preclinical